Loading…
Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis
Objective To investigate the clinical significance of the expression of the NKG2D ligands MICA/B and ULBP2 in ovarian cancer. Methods Eighty-two ovarian cancer patients and six patients without ovarian cancer from Department of Obstetrics and Gynecology of Kyoto University Hospital were enrolled in...
Saved in:
| Published in: | Cancer Immunology, Immunotherapy Immunotherapy, 2009-05, Vol.58 (5), p.641-652 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c619t-b6144b902660ed8ffe05a34fd3221549d1e72c891d0bbb89a9499faea61a09263 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c619t-b6144b902660ed8ffe05a34fd3221549d1e72c891d0bbb89a9499faea61a09263 |
| container_end_page | 652 |
| container_issue | 5 |
| container_start_page | 641 |
| container_title | Cancer Immunology, Immunotherapy |
| container_volume | 58 |
| creator | Li, Kui Mandai, Masaki Hamanishi, Junzo Matsumura, Noriomi Suzuki, Ayako Yagi, Haruhiko Yamaguchi, Ken Baba, Tsukasa Fujii, Shingo Konishi, Ikuo |
| description | Objective To investigate the clinical significance of the expression of the NKG2D ligands MICA/B and ULBP2 in ovarian cancer. Methods Eighty-two ovarian cancer patients and six patients without ovarian cancer from Department of Obstetrics and Gynecology of Kyoto University Hospital were enrolled in this study between 1993 and 2003. Expression of MICA/B, ULBP2, and CD57 in ovarian cancer tissue and normal ovary tissue was evaluated by immunohistochemical staining, and the relationship of these results to relevant clinical patient data was analyzed. Expression of MICs, ULBP2, and HLA-class I molecules in 33 ovarian cancer cell lines and two normal ovarian epithelial cell lines, as well as levels of soluble MICs and ULBP2 in the culture supernatants, were measured. Results Expression of MICA/B and ULBP2 was detected in 97.6 and 82.9% of ovarian cancer cells, respectively, whereas neither was expressed on normal ovarian epithelium. The expression of MICA/B in ovarian cancer was highly correlated with that of ULBP2. Strong expression of ULBP2 in ovarian cancer cells was correlated with less intraepithelial infiltration of T cells and bad prognoses for patients, suggesting that ULBP2 expression is a prognostic indicator in ovarian cancer. The expression of NKG2D ligands did not correlate with the levels of the soluble forms of the ligands. Conclusions High expression of ULBP2 is an indicator of poor prognosis in ovarian cancer and may relate to T cell dysfunction in the tumor microenvironment. |
| doi_str_mv | 10.1007/s00262-008-0585-3 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11030581</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20464555</sourcerecordid><originalsourceid>FETCH-LOGICAL-c619t-b6144b902660ed8ffe05a34fd3221549d1e72c891d0bbb89a9499faea61a09263</originalsourceid><addsrcrecordid>eNqFkt2O0zAQhSMEYsvCA3ADFhJcEXbGdn68N4gtsCDKjwS9tpzESb1K7WK3K3gFnpoJrXaBC7iy4_nOGXtysuw-wjMEqE4SAC95DlDnUNRFLm5kM5SCTuoCb2YzEBLyCkAeZXdSuqANB6VuZ0dYVworFLPsx3x03rVmZMkN3vW09a1loWfblWUf3p3zl2x0g_Fdesrev52_ODlj9MGWi7NPnDnPwqWJznj2SxdP2coNK2a_baJNyQU_OR3YREJSdNRiG-JU2ARaNzEMPiSX7ma3ejMme--wHmfL16--zN_ki4_n1HiRtyWqbd6UKGWj6OUl2K7uewuFEbLvBOdYSNWhrXhbK-ygaZpaGSWV6o01JRpQvBTH2fO972bXrG3XWr-NZtSb6NYmftfBOP1nxbuVHsKlRgRBc0ZyeHJwiOHrzqatXrvU2nE03oZd0mWpComi-C_IQZayKCbw0V_gRdhFT2PQnIw4p64E4R5qY0gp2v7qzgh6CoTeB0JTIPQUCD1pHvz-2GvFIQEEPD4AJlEM-kj_0aUrjiPnQoiKOL7nEpX8YOP1Df_V_eFe1JugzRDJePmZAwrAQtGMhPgJiyXVIg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213522813</pqid></control><display><type>article</type><title>Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis</title><source>Springer Nature</source><source>PubMed Central</source><creator>Li, Kui ; Mandai, Masaki ; Hamanishi, Junzo ; Matsumura, Noriomi ; Suzuki, Ayako ; Yagi, Haruhiko ; Yamaguchi, Ken ; Baba, Tsukasa ; Fujii, Shingo ; Konishi, Ikuo</creator><creatorcontrib>Li, Kui ; Mandai, Masaki ; Hamanishi, Junzo ; Matsumura, Noriomi ; Suzuki, Ayako ; Yagi, Haruhiko ; Yamaguchi, Ken ; Baba, Tsukasa ; Fujii, Shingo ; Konishi, Ikuo</creatorcontrib><description>Objective To investigate the clinical significance of the expression of the NKG2D ligands MICA/B and ULBP2 in ovarian cancer. Methods Eighty-two ovarian cancer patients and six patients without ovarian cancer from Department of Obstetrics and Gynecology of Kyoto University Hospital were enrolled in this study between 1993 and 2003. Expression of MICA/B, ULBP2, and CD57 in ovarian cancer tissue and normal ovary tissue was evaluated by immunohistochemical staining, and the relationship of these results to relevant clinical patient data was analyzed. Expression of MICs, ULBP2, and HLA-class I molecules in 33 ovarian cancer cell lines and two normal ovarian epithelial cell lines, as well as levels of soluble MICs and ULBP2 in the culture supernatants, were measured. Results Expression of MICA/B and ULBP2 was detected in 97.6 and 82.9% of ovarian cancer cells, respectively, whereas neither was expressed on normal ovarian epithelium. The expression of MICA/B in ovarian cancer was highly correlated with that of ULBP2. Strong expression of ULBP2 in ovarian cancer cells was correlated with less intraepithelial infiltration of T cells and bad prognoses for patients, suggesting that ULBP2 expression is a prognostic indicator in ovarian cancer. The expression of NKG2D ligands did not correlate with the levels of the soluble forms of the ligands. Conclusions High expression of ULBP2 is an indicator of poor prognosis in ovarian cancer and may relate to T cell dysfunction in the tumor microenvironment.</description><identifier>ISSN: 0340-7004</identifier><identifier>EISSN: 1432-0851</identifier><identifier>DOI: 10.1007/s00262-008-0585-3</identifier><identifier>PMID: 18791713</identifier><identifier>CODEN: CIIMDN</identifier><language>eng</language><publisher>Berlin/Heidelberg: Berlin/Heidelberg : Springer-Verlag</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic agents ; Biological and medical sciences ; Cancer Research ; Carcinoma - chemistry ; Carcinoma - immunology ; Carcinoma - mortality ; CD57 Antigens - analysis ; CD8-Positive T-Lymphocytes - immunology ; Culture Media, Conditioned - chemistry ; Disease-Free Survival ; Epithelial Cells - chemistry ; Female ; Female genital diseases ; GPI-Linked Proteins ; Gynecology. Andrology. Obstetrics ; Histocompatibility Antigens Class I - analysis ; HLA Antigens - analysis ; Humans ; Immunology ; Immunotherapy ; Intercellular Signaling Peptides and Proteins - analysis ; Intercellular Signaling Peptides and Proteins - physiology ; Kaplan-Meier Estimate ; Killer Cells, Natural - immunology ; Lymphocytes, Tumor-Infiltrating - immunology ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Proteins - analysis ; Neoplasm Proteins - physiology ; NK Cell Lectin-Like Receptor Subfamily K - physiology ; Oncology ; Original ; Original Article ; Ovarian cancer ; Ovarian Neoplasms - chemistry ; Ovarian Neoplasms - immunology ; Ovarian Neoplasms - mortality ; Ovary - chemistry ; Pharmacology. Drug treatments ; Prognosis ; Tumors</subject><ispartof>Cancer Immunology, Immunotherapy, 2009-05, Vol.58 (5), p.641-652</ispartof><rights>Springer-Verlag 2008</rights><rights>2009 INIST-CNRS</rights><rights>Springer-Verlag 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c619t-b6144b902660ed8ffe05a34fd3221549d1e72c891d0bbb89a9499faea61a09263</citedby><cites>FETCH-LOGICAL-c619t-b6144b902660ed8ffe05a34fd3221549d1e72c891d0bbb89a9499faea61a09263</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11030581/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11030581/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21223337$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18791713$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Kui</creatorcontrib><creatorcontrib>Mandai, Masaki</creatorcontrib><creatorcontrib>Hamanishi, Junzo</creatorcontrib><creatorcontrib>Matsumura, Noriomi</creatorcontrib><creatorcontrib>Suzuki, Ayako</creatorcontrib><creatorcontrib>Yagi, Haruhiko</creatorcontrib><creatorcontrib>Yamaguchi, Ken</creatorcontrib><creatorcontrib>Baba, Tsukasa</creatorcontrib><creatorcontrib>Fujii, Shingo</creatorcontrib><creatorcontrib>Konishi, Ikuo</creatorcontrib><title>Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis</title><title>Cancer Immunology, Immunotherapy</title><addtitle>Cancer Immunol Immunother</addtitle><addtitle>Cancer Immunol Immunother</addtitle><description>Objective To investigate the clinical significance of the expression of the NKG2D ligands MICA/B and ULBP2 in ovarian cancer. Methods Eighty-two ovarian cancer patients and six patients without ovarian cancer from Department of Obstetrics and Gynecology of Kyoto University Hospital were enrolled in this study between 1993 and 2003. Expression of MICA/B, ULBP2, and CD57 in ovarian cancer tissue and normal ovary tissue was evaluated by immunohistochemical staining, and the relationship of these results to relevant clinical patient data was analyzed. Expression of MICs, ULBP2, and HLA-class I molecules in 33 ovarian cancer cell lines and two normal ovarian epithelial cell lines, as well as levels of soluble MICs and ULBP2 in the culture supernatants, were measured. Results Expression of MICA/B and ULBP2 was detected in 97.6 and 82.9% of ovarian cancer cells, respectively, whereas neither was expressed on normal ovarian epithelium. The expression of MICA/B in ovarian cancer was highly correlated with that of ULBP2. Strong expression of ULBP2 in ovarian cancer cells was correlated with less intraepithelial infiltration of T cells and bad prognoses for patients, suggesting that ULBP2 expression is a prognostic indicator in ovarian cancer. The expression of NKG2D ligands did not correlate with the levels of the soluble forms of the ligands. Conclusions High expression of ULBP2 is an indicator of poor prognosis in ovarian cancer and may relate to T cell dysfunction in the tumor microenvironment.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Cancer Research</subject><subject>Carcinoma - chemistry</subject><subject>Carcinoma - immunology</subject><subject>Carcinoma - mortality</subject><subject>CD57 Antigens - analysis</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>Culture Media, Conditioned - chemistry</subject><subject>Disease-Free Survival</subject><subject>Epithelial Cells - chemistry</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>GPI-Linked Proteins</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Histocompatibility Antigens Class I - analysis</subject><subject>HLA Antigens - analysis</subject><subject>Humans</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Intercellular Signaling Peptides and Proteins - analysis</subject><subject>Intercellular Signaling Peptides and Proteins - physiology</subject><subject>Kaplan-Meier Estimate</subject><subject>Killer Cells, Natural - immunology</subject><subject>Lymphocytes, Tumor-Infiltrating - immunology</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Proteins - analysis</subject><subject>Neoplasm Proteins - physiology</subject><subject>NK Cell Lectin-Like Receptor Subfamily K - physiology</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - chemistry</subject><subject>Ovarian Neoplasms - immunology</subject><subject>Ovarian Neoplasms - mortality</subject><subject>Ovary - chemistry</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>Tumors</subject><issn>0340-7004</issn><issn>1432-0851</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqFkt2O0zAQhSMEYsvCA3ADFhJcEXbGdn68N4gtsCDKjwS9tpzESb1K7WK3K3gFnpoJrXaBC7iy4_nOGXtysuw-wjMEqE4SAC95DlDnUNRFLm5kM5SCTuoCb2YzEBLyCkAeZXdSuqANB6VuZ0dYVworFLPsx3x03rVmZMkN3vW09a1loWfblWUf3p3zl2x0g_Fdesrev52_ODlj9MGWi7NPnDnPwqWJznj2SxdP2coNK2a_baJNyQU_OR3YREJSdNRiG-JU2ARaNzEMPiSX7ma3ejMme--wHmfL16--zN_ki4_n1HiRtyWqbd6UKGWj6OUl2K7uewuFEbLvBOdYSNWhrXhbK-ygaZpaGSWV6o01JRpQvBTH2fO972bXrG3XWr-NZtSb6NYmftfBOP1nxbuVHsKlRgRBc0ZyeHJwiOHrzqatXrvU2nE03oZd0mWpComi-C_IQZayKCbw0V_gRdhFT2PQnIw4p64E4R5qY0gp2v7qzgh6CoTeB0JTIPQUCD1pHvz-2GvFIQEEPD4AJlEM-kj_0aUrjiPnQoiKOL7nEpX8YOP1Df_V_eFe1JugzRDJePmZAwrAQtGMhPgJiyXVIg</recordid><startdate>20090501</startdate><enddate>20090501</enddate><creator>Li, Kui</creator><creator>Mandai, Masaki</creator><creator>Hamanishi, Junzo</creator><creator>Matsumura, Noriomi</creator><creator>Suzuki, Ayako</creator><creator>Yagi, Haruhiko</creator><creator>Yamaguchi, Ken</creator><creator>Baba, Tsukasa</creator><creator>Fujii, Shingo</creator><creator>Konishi, Ikuo</creator><general>Berlin/Heidelberg : Springer-Verlag</general><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20090501</creationdate><title>Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis</title><author>Li, Kui ; Mandai, Masaki ; Hamanishi, Junzo ; Matsumura, Noriomi ; Suzuki, Ayako ; Yagi, Haruhiko ; Yamaguchi, Ken ; Baba, Tsukasa ; Fujii, Shingo ; Konishi, Ikuo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c619t-b6144b902660ed8ffe05a34fd3221549d1e72c891d0bbb89a9499faea61a09263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Cancer Research</topic><topic>Carcinoma - chemistry</topic><topic>Carcinoma - immunology</topic><topic>Carcinoma - mortality</topic><topic>CD57 Antigens - analysis</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>Culture Media, Conditioned - chemistry</topic><topic>Disease-Free Survival</topic><topic>Epithelial Cells - chemistry</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>GPI-Linked Proteins</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Histocompatibility Antigens Class I - analysis</topic><topic>HLA Antigens - analysis</topic><topic>Humans</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Intercellular Signaling Peptides and Proteins - analysis</topic><topic>Intercellular Signaling Peptides and Proteins - physiology</topic><topic>Kaplan-Meier Estimate</topic><topic>Killer Cells, Natural - immunology</topic><topic>Lymphocytes, Tumor-Infiltrating - immunology</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Proteins - analysis</topic><topic>Neoplasm Proteins - physiology</topic><topic>NK Cell Lectin-Like Receptor Subfamily K - physiology</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - chemistry</topic><topic>Ovarian Neoplasms - immunology</topic><topic>Ovarian Neoplasms - mortality</topic><topic>Ovary - chemistry</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Kui</creatorcontrib><creatorcontrib>Mandai, Masaki</creatorcontrib><creatorcontrib>Hamanishi, Junzo</creatorcontrib><creatorcontrib>Matsumura, Noriomi</creatorcontrib><creatorcontrib>Suzuki, Ayako</creatorcontrib><creatorcontrib>Yagi, Haruhiko</creatorcontrib><creatorcontrib>Yamaguchi, Ken</creatorcontrib><creatorcontrib>Baba, Tsukasa</creatorcontrib><creatorcontrib>Fujii, Shingo</creatorcontrib><creatorcontrib>Konishi, Ikuo</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer Immunology, Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Kui</au><au>Mandai, Masaki</au><au>Hamanishi, Junzo</au><au>Matsumura, Noriomi</au><au>Suzuki, Ayako</au><au>Yagi, Haruhiko</au><au>Yamaguchi, Ken</au><au>Baba, Tsukasa</au><au>Fujii, Shingo</au><au>Konishi, Ikuo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis</atitle><jtitle>Cancer Immunology, Immunotherapy</jtitle><stitle>Cancer Immunol Immunother</stitle><addtitle>Cancer Immunol Immunother</addtitle><date>2009-05-01</date><risdate>2009</risdate><volume>58</volume><issue>5</issue><spage>641</spage><epage>652</epage><pages>641-652</pages><issn>0340-7004</issn><eissn>1432-0851</eissn><coden>CIIMDN</coden><abstract>Objective To investigate the clinical significance of the expression of the NKG2D ligands MICA/B and ULBP2 in ovarian cancer. Methods Eighty-two ovarian cancer patients and six patients without ovarian cancer from Department of Obstetrics and Gynecology of Kyoto University Hospital were enrolled in this study between 1993 and 2003. Expression of MICA/B, ULBP2, and CD57 in ovarian cancer tissue and normal ovary tissue was evaluated by immunohistochemical staining, and the relationship of these results to relevant clinical patient data was analyzed. Expression of MICs, ULBP2, and HLA-class I molecules in 33 ovarian cancer cell lines and two normal ovarian epithelial cell lines, as well as levels of soluble MICs and ULBP2 in the culture supernatants, were measured. Results Expression of MICA/B and ULBP2 was detected in 97.6 and 82.9% of ovarian cancer cells, respectively, whereas neither was expressed on normal ovarian epithelium. The expression of MICA/B in ovarian cancer was highly correlated with that of ULBP2. Strong expression of ULBP2 in ovarian cancer cells was correlated with less intraepithelial infiltration of T cells and bad prognoses for patients, suggesting that ULBP2 expression is a prognostic indicator in ovarian cancer. The expression of NKG2D ligands did not correlate with the levels of the soluble forms of the ligands. Conclusions High expression of ULBP2 is an indicator of poor prognosis in ovarian cancer and may relate to T cell dysfunction in the tumor microenvironment.</abstract><cop>Berlin/Heidelberg</cop><pub>Berlin/Heidelberg : Springer-Verlag</pub><pmid>18791713</pmid><doi>10.1007/s00262-008-0585-3</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-7004 |
| ispartof | Cancer Immunology, Immunotherapy, 2009-05, Vol.58 (5), p.641-652 |
| issn | 0340-7004 1432-0851 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11030581 |
| source | Springer Nature; PubMed Central |
| subjects | Adult Aged Aged, 80 and over Antineoplastic agents Biological and medical sciences Cancer Research Carcinoma - chemistry Carcinoma - immunology Carcinoma - mortality CD57 Antigens - analysis CD8-Positive T-Lymphocytes - immunology Culture Media, Conditioned - chemistry Disease-Free Survival Epithelial Cells - chemistry Female Female genital diseases GPI-Linked Proteins Gynecology. Andrology. Obstetrics Histocompatibility Antigens Class I - analysis HLA Antigens - analysis Humans Immunology Immunotherapy Intercellular Signaling Peptides and Proteins - analysis Intercellular Signaling Peptides and Proteins - physiology Kaplan-Meier Estimate Killer Cells, Natural - immunology Lymphocytes, Tumor-Infiltrating - immunology Medical sciences Medicine Medicine & Public Health Middle Aged Neoplasm Proteins - analysis Neoplasm Proteins - physiology NK Cell Lectin-Like Receptor Subfamily K - physiology Oncology Original Original Article Ovarian cancer Ovarian Neoplasms - chemistry Ovarian Neoplasms - immunology Ovarian Neoplasms - mortality Ovary - chemistry Pharmacology. Drug treatments Prognosis Tumors |
| title | Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T18%3A36%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20significance%20of%20the%20NKG2D%20ligands,%20MICA/B%20and%20ULBP2%20in%20ovarian%20cancer:%20high%20expression%20of%20ULBP2%20is%20an%20indicator%20of%20poor%20prognosis&rft.jtitle=Cancer%20Immunology,%20Immunotherapy&rft.au=Li,%20Kui&rft.date=2009-05-01&rft.volume=58&rft.issue=5&rft.spage=641&rft.epage=652&rft.pages=641-652&rft.issn=0340-7004&rft.eissn=1432-0851&rft.coden=CIIMDN&rft_id=info:doi/10.1007/s00262-008-0585-3&rft_dat=%3Cproquest_pubme%3E20464555%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c619t-b6144b902660ed8ffe05a34fd3221549d1e72c891d0bbb89a9499faea61a09263%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=213522813&rft_id=info:pmid/18791713&rfr_iscdi=true |